TLPPF Stock Chart & Stats
$10.48
-$0.46(-4.37%)
At close: 4:00 PM EDT
$10.48
-$0.46(-4.37%)
Day’s Range― - ―
52-Week Range$5.91 - $12.50
Previous CloseN/A
Volume1.10K
Average Volume (3M)5.55K
Market Cap
$3.94B
Enterprise Value$6.39K
Total Cash (Recent Filing)$363.61M
Total Debt (Recent Filing)$836.98M
Price to Earnings (P/E)111.9
Beta1.44
Next Earnings
Feb 19, 2027EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding339,784,300
10 Day Avg. Volume886
30 Day Avg. Volume5,548
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.03Price Target Upside72.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.02
Revenue Forecast (FY)$702.02M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained double-digit growth, led by Precision Medicine, demonstrates strong product adoption and commercial execution. Management’s maintained full-year guidance and expectation of landing near the upper end support continued revenue expansion over the next several quarters.
Improving Margins And ProfitabilityHigher gross margins and operating leverage indicate improving product economics as the commercial base scales. Cost discipline, rising EBITDA and positive H1 net profit provide evidence that growth can increasingly translate into earnings rather than relying solely on expansion.
Growing Market Position And CapabilityRepeated share gains and international expansion strengthen Telix’s commercial position in radiopharmaceutical imaging. Manufacturing and distribution investments, including RLS integration, can improve supply reliability and support broader product and therapeutic rollout.
Bears Say
Rising LeverageA faster increase in debt than equity reduces financial flexibility and raises refinancing and interest burden risks. This is especially important while earnings remain volatile, because weaker profitability could constrain investment capacity or increase dependence on external funding.
Weak Recent Cash ConversionThe reversal to negative operating and free cash flow suggests that growth is currently absorbing substantial working capital or investment. Persistent weak conversion could pressure funding needs and limit the company’s ability to finance pipeline expansion internally.
Regulatory And Investment Execution RiskThe Zircaix setback delays a potential product contribution and highlights manufacturing-readiness risk in a regulated business. At the same time, elevated R&D investment increases execution and funding requirements before pipeline programs can generate commercial returns.
Telix Pharmaceuticals News
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $5.91 and its highest was $12.50 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $3.94B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2027 which is in 176 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.15.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.01.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,784,300 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $0.17 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 1.431%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.03 (72.03% Upside)
$18.03 (72.03% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 95%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $96.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLPPF Company Deck
TLPPF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.View all TLPPF earnings summariesTLPPF Stock 12 Month Forecast
Average Price Target
$18.03
▲(72.03% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Ownership Overview
6.30% Insiders
0.86% Mutual Funds
― Other Institutional Investors
88.49% Public Companies and
Individual Investors